SCHEDULE: Benjamin Weinstein Increases Stake in Precision BioSciences

Benjamin Weinstein has updated his beneficial ownership filing for Precision BioSciences Inc., now holding 4.0% of the company's common stock.

Summary

• Benjamin Weinstein has filed an amendment to his Schedule 13G, reporting beneficial ownership of Precision BioSciences Inc. common stock.
• As of August 21, 2026, Weinstein beneficially owns 1,105,720 shares of common stock.
• This ownership represents 4.0% of the company's outstanding common stock.
• The reported shares include 203,500 shares issuable upon the exercise of warrants.
• The calculation of the percentage is based on 27,601,554 shares of common stock outstanding as of August 3, 2026, as per the company's Form 10-Q.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership, with no significant new financial or strategic information.

Positives

• Increased transparency regarding significant shareholder holdings.
• Indicates continued investment interest from Benjamin Weinstein.

Negatives

• No new financial performance data or strategic initiatives are disclosed.
• The filing does not provide insight into the reasons for the share acquisition or future intentions.

Risks

• The filing does not explicitly mention any new risks.
• Potential for future share price volatility if Weinstein's intentions are perceived negatively by the market.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for significant beneficial ownership changes. This filing indicates Benjamin Weinstein's continued, albeit passive, interest in Precision BioSciences, without suggesting any immediate strategic shift or control intent.

Stakeholder Impact

• Shareholders: May note the increased stake as a sign of investor confidence, but the passive nature of the filing limits immediate impact.
• Management: The filing confirms Weinstein's passive investment status, not indicating an intent to influence control.
• Creditors: No direct impact as the filing concerns equity ownership.

Next Steps

• Continued monitoring of Precision BioSciences' financial and strategic developments.
• Further filings from Benjamin Weinstein if his beneficial ownership changes significantly.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Precision BioSciences, common stock, warrants, shareholder